Skip to main content
Premium Trial:

Request an Annual Quote

Medix Biochemica Acquires IVD Raw Materials Maker Bioresource Technology

NEW YORK — Medix Biochemica, a Finnish producer of raw materials for in vitro diagnostics, said on Monday that it has acquired Bioresource Technology, a US-based provider of base matrices and other raw materials for IVD manufacturing.

According to Medix, Bioresource Technology focuses on immunoassay, clinical chemistry, and molecular diagnostic assay and quality control materials, which are manufactured at its facility in Weston, Florida. It has about 20 employees.

Bioresource Technology will be integrated into Medix's St. Louis-based IVD Biomaterials Business Unit, which makes native antigens, enzymes, proteins, and biologicals, but will continue to operate in Florida.

Financial and other terms of the deal were not disclosed.

"There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products," Medix CEO Steve Ferguson said in a statement. "With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens, and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need."